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ARTICLE

Pharmacometabolomics of Respiratory Phenotypic
Response to Dexamethasone in Preterm Infants at Risk
for Bronchopulmonary Dysplasia
Tamorah Lewis1,*

, Prabhakar Chalise2

, Cheri Gauldin1 and William Truog1

A prospective cohort study was performed in preterm infants less than 32 weeks gestation at birth who were treated with
dexamethasone for developing or established bronchopulmonary dysplasia (BPD). Respiratory phenotype (Respiratory
Severity Score (RSS)), serum, and urine metabolomics were assessed before and after treatment. Ten infants provided nine
matched serum and nine matched urine samples. There was a significant decrease in RSS with steroid treatment. Serum
gluconic acid had the largest median fold change (140 times decreased, P = 0.008). In metabolite set enrichment analysis,
in both serum and urine, the urea cycle, ammonia recycling, and malate-aspartate shuttle pathways were most significantly
enriched when comparing pretreatment and post-treatment (P value < 0.05). In regression analyses, 6 serum and 28 urine
metabolites were significantly associated with change in RSS. Urine gluconic acid lactone was the most significantly correlated with clinical response (correlational coefficient 0.915). Pharmacometabolomic discovery of drug response biomarkers
in preterm infants may allow precision therapeutics in BPD treatment.

Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔ Bronchopulmonary dysplasia (BPD) is a common lung
disease among preterm infants. Corticosteroids can improve symptoms, but there is large unexplained variability
in clinical response. Pharmacometabolomics is an emerging tool to help understand variability in drug response.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔ Are there serum and plasma metabolomic changes associated with dexamethasone therapy? Do certain metabolomic changes correlate with degree of drug response?
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔ This first pharmacometabolomic study in preterm infants with BPD shows that gluconic acid has the largest

Bronchopulmonary dysplasia (BPD) is a lung disease
that results from the combination of preterm birth, ventilator-associated lung injury, inflammation, and maladaptive
lung growth. BPD is a common diagnosis in the neonatal
intensive care unit (NICU), but there are no US Food and
Drug Administration (FDA)- approved therapies for management. One class of drugs commonly used to prevent severe BPD, or to treat established BPD, are corticosteroids.1
Use of this drug class in neonates and infants with BPD is
challenging because of variability in clinical wanted effects

fold change with steroid treatment and that the degree
of change in urine gluconic acid correlates with drug response. Metabolic pathways are altered with dexamethasone therapy and certain metabolic signatures may be
able to differentiate responders from nonresponders.
HOW MIGHT THIS CHANGE CLINICAL PHARMA
COLOGY OR TRANSLATIONAL SCIENCE?
✔ Identification of metabolomic biomarkers for likelihood
of drug response, ones that could be measured early in
treatment, may allow for precision therapeutics and early
stopping of a high risk drug among infants unlikely to
respond.

and an inability to target infants who are likely “responders.”
Neonatologists lack an early biomarker of likely drug effect
and cannot personalize therapy to improve outcomes.
Pharmacometabolomics is a novel and powerful tool to
help understand variability in drug response. A patient metabotype, or the full complement of circulating molecules
in the plasma or urine, can be defined pretreatment and
post-treatment with a drug. Either baseline metabotype or
change in metabotype, in conjunction with close measurement of drug response, can inform treatment outcomes.
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Metabotype at baseline, and the discovery of signature
metabotype changes with certain drug exposures, can elucidate the mechanisms of variation in drug response. For
example, if a metabolic signature of responders vs. nonresponders was available before treatment or early in the
drug treatment course, then infants in the nonresponder
group could receive alternate therapies empirically, or at
least be spared the full 7–10 day course of steroids, which
have been associated with adverse outcomes.2,3
Given the variability in steroid response observed in clinical practice, our goal is to perform a prospective cohort steroid pharmacometabolomic study nested in routine clinical
care of preterm infants with evolving or established BPD.
During this exploratory project, we aim to identify metabolomic changes that correlate with drug response and drug failure. Because neonatal metabolomics is an emerging field,
our group aims to discover treatment response biomarkers
and generate hypotheses for future research.

or noninvasive ventilation. Lower values of the RSS indicates
better pulmonary function. RSS is calculated as the mean
airway pressure × fractioned of inspired oxygen (FiO2) (ranging
from 21−100%). After starting treatment with dexamethasone,
clinicians want the RSS to go down as pulmonary mechanics
and gas exchange improve.
Blood and urine samples were collected two times, once
in the 24 hours prior to starting systemic dexamethasone
and once at days 3–6 after starting systemic dexamethasone. Both matrices were studied because the urine can
be collected noninvasively with a cotton ball, whereas the
serum may be a better reflection of pulmonary changes. The
timing of post-treatment blood and urine sample was dictated by the infant having blood drawn for clinical laboratories within the target window. Samples were collected in
the NICU and then either briefly refrigerated or immediately
processed. Urine and serum were aliquoted and stored at
−80℃ until metabolomic assay.

METHODS
Subjects and study design
This prospective pilot cohort study was reviewed and approved by the Children’s Mercy Hospital institutional review
board prior to patient enrollment. Parental consent was obtained in accordance with institutional review board regulations. Starting in October 2016, all preterm infants less
than 32 weeks gestation at birth and treated with systemic
dexamethasone per clinical care were eligible for enrollment. Demographic data and clinical data were abstracted
from the clinical chart and by speaking with bedside clinicians in realtime. For this analysis, we only used data from
the first course of systemic dexamethasone for each child.
In order to measure the clinical outcome, we measured shortterm phenotypic response to systemic corticosteroids. The
Respiratory Severity Score (RSS) was calculated before treatment (baseline) and on day 7 of treatment (drug response). In
order to account for intraindividual variability, the average RSS
for a 24-hour period was collected. The RSS is a quantitative
description of the severity of lung disease while on mechanical

Untargeted metabolomic assessment
Serum and urine samples were submitted for an untargeted
metabolomic analysis through the National Institutes of
Health (NIH)-funded West Coast Metabolomics Center in
Davis, California. For analysis of serum and urine metabolites, metabolite levels were determined using an Agilent
7890A gas chromatograph coupled to a Leco Pegasus IV
time-of-flight mass spectrometer, as previously described.4
Acquired spectra were further processed using the 130
BinBase database,4,5 including metabolite annotations by
retention index and mass spectra matching. Data, reported
as quantitative ion peak heights, were normalized by the
sum intensity of all annotated metabolites across the entire
study and used for further statistical analysis.
Statistical analysis
The change in RSS, the clinical outcome, was assessed
before and after treatment using the Wilcoxon signed rank
test. In order to test for an association between baseline metabolite level and change in RSS, we performed regression

Table 1. Demographic and respiratory data

Infant
1

GA (weeks)

BW (kg)

Race

DOL
steroid

25 1/7

0.480

WH

138

11.02

0.50 (nasal
cannula)

Pre-RSS

Post-RSS

Change in
RSS

Sample
collec
tion

Serum
analysis

Urine
analysis

−10.52

7.3

x

x

2

25 0/7

0.420

AA

36

4.65

2.63

−2.02

3.50

x

x

3

23 4/7

0.625

HIS

26

9.75

3.87

−5.88

5.33

x

x

4

23 4/7

0.595

HIS

27

8.03

2.90

−5.13

4.38

x

x

5

25 2/7

0.725

HIS

36

3.96

2.31

−1.65

5.63

x

x

6

24 6/7

0.700

WH

73

4.40

2.43

−1.97

6.58

x

x
—

7

28 6/7

1.530

WH

26

7.80

2.99

−4.81

4.42

x

8

24 4/7

0.370

AA

127

8.78

8.16

−0.6

5.54

x

x

9

25 5/7

0.850

WH

33

5.16

2.57

−2.59

6.50

—

x

10

26 4/7

0.770

WH

111

2.34

0.50

−1.84

3.50

x

x

Median

25 0/7

0.663

—

36

6.48

2.6

−2.3

5.44

—

—

24 2/7–26 0/7

0.465–0.790

—

27–115

4.29–9.02

1.86–3.21

−5.32 to −1.79

4.16–6.52

—

—

IQR

AA, African American; BW, birthweight; DOL steroid, day of life (age) when infant started steroids; GA, gestational age; HIS, Hispanic; IQR, interquartile
range; RSS, Respiratory Severity Score; Sample collection, number of days from steroid start to post-treatment metabolomic sample collection; WH, white.
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analysis. The differences in the metabolites assayed before and after treatment were assessed using the Wilcoxon
signed rank test for each metabolite followed by multiple
testing adjustments using Benjamini and Hochberg’s false
discovery rate method.
Each metabolite change was assessed from pretreatment
to post-treatment using the Wilcoxon signed rank test and
then they were sorted by the order of significance (P value).
Then, Metabolite Set Enrichment Analysis (MSEA) was completed, as previously described6,7 using MetaboAnalyst
version 4.0. MSEA is a method of identifying biologically
(a)

12

Serum Samples

Pre
Post

Median Pre = 7.8
Median Post = 2.63
p−value = 0.0039

Median Pre = 5.16
Median Post = 2.5667
p−value = 0.0039

2

4

6

8

10

Pre
Post

Urine Samples

0

Respiratory Severity Score

meaningful patterns or the metabolic pathways that are significantly enriched in quantitative metabolomic data. The
MSEA as implemented in the MetaboAnalyst version 4.06
uses the hypergeometric distribution based test followed
by multiple test adjustments to evaluate whether a particular metabolite set is represented more than expected by
chance within the given compound list.
Next, the association of change in metabolites with the
change in the RSS scores before and after treatment was investigated using linear regression and correlation analyses.
Prior to fitting the linear regression models, the association

Pre

Post

Pre

Post

Trans-4-hydroxyproline

(b)

Serum

Pre
Post

Post

Pre

Post

Urine

Pre

Figure 1. Change in phenotype and example metabolite with dexamethasone therapy. Boxplots displaying (a) change in Respiratory
Severity Score and (b) change in trans-4-hydroxyproline, an example metabolite that nearly universally decreased with steroid
treatment.
www.cts-journal.com
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of RSS with the birth weight, gender, race, mode of delivery, and antenatal steroids were examined. None of the variables were found to be associated with the RSS for both
serum and urine, so they were not included in the regression model. Finally, for the exploratory analysis, the subjects
were grouped into good, moderate, and poor responders’
categories based on a decrease in RSS score. The top three
subjects that had maximum decrease in RSS score were
categorized as “good” responders, the three subjects having the least decrease in RSS were categorized as “poor” responders, and the remaining as “moderate” responders. The
differences in the changes in metabolites among the three
groups were assessed using the Kruskal−Wallis test. The
tests were considered significant if the P value was <0.05.

The analyses were carried out separately for the serum
and urine. All the analyses were performed using Statistical
Software R (R Foundation for Statistical Computing, Vienna,
Austria) and MetaboAnalyst version 4.0.
RESULTS
Ten infants (median birthweight 663 g; median gestational
age 25 0/7 weeks) provided nine matched pre-steroid and
post-steroid treatment serum samples and nine matched
pre-steroid and post-steroid treatment urine samples for
analysis. Infant demographic and clinical phenotypic response data are provided in Table 1. All infants were treated
with a protocolized dexamethasone wean over 7–10 days

Table 2. Metabolite changes with dexamethasone therapy
Fold change

Direction

P valuea

15,403

1.425148

Up

0.0039

81,823

1.977786

Up

0.0039

405

837

2.066667

Up

0.0078

115,513

826

0.007151

Down

0.0078

Caprylic acid

902

4,800

5.321508

Up

0.0078

Alpha-ketoglutarate

669

958

1.431988

Up

0.0117

8,474

868

0.102431

Down

0.0273

Metabolites

Median (pre)

Median (post)

Oxalic acid

10,808

Lactic acid

41,371

Malic acid

Serum

Gluconic acidb

Saccharic acidb
Cholesterol

1,581

2,221

1.404807

Up

0.0273

Arachidic acid

2,671

3,980

1.490079

Up

0.0273

Fumaric acid

524

1,049

2.001908

Up

0.038

Stearic acid

163,353

180,749

1.106493

Up

0.0391

Xylitol

1,103

875

0.793291

Down

0.0547

Tryptophan

49,903

27,348

0.548023

Down

0.0547

Trans-4-hydroxyproline

10,342

5,637

0.545059

Down

0.0547

700

502

0.717143

Down

0.0547

P-hydroxylphenyllactic acid
Beta-gentiobiose

1,613

2,416

1.49783

Up

0.0547

Pantothenic acid

8,145

2,066

0.253653

Down

0.0587

Uracil

4,621

6,056

1.310539

Up

0.0039

Kynurenine

13,311

7,034

0.528435

Down

0.0039

Glucoheptulose

8,065

10,322

1.279851

Up

0.0039

Urine

1-Methylinosine

7,752

4,910

0.633385

Down

0.0039

Pseudo uridine

1,644,332

1,189,538

0.723417

Down

0.0078

Isohexonic acid

1,798,781

115,773

0.064362

Down

0.0078

295,790

390,974

1.321796

Up

0.0078

21,523

7,731

0.359197

Down

0.0117

7232

15,092

2.086836

Up

0.0195

Histidine
Indole-3-lactate
Sucrose
Nicotinamide

45,119

33,991

0.753363

Down

0.0195

7-Methylguanine

40,803

29,360

0.719555

Down

0.0195

5-Hydroxymethyl-2-furoic acid

53,570

28,530

0.532574

Down

0.0195

Pipecolinic acid

4,543

2,124

0.467532

Down

0.0273

1,3,5-Trimethylcyanuric acid

64,839

50,777

0.783124

Down

0.0273

1,2-Cyclohexanedione

40,847

28,027

0.686146

Down

0.0391

Uridine b

1,028

878

0.854086

Down

0.0547

Metanephrine

48,104

40,710

0.846291

Down

0.0547

Ascorbic acid

35,228

107,869

3.062025

Up

0.0547

Bold: Metabolite found significant in both pre–post comparison and regression analysis.
Italics: P value between 0.05 and 0.06, data included to encourage hypothesis generation.
a
P value displayed in table is unadjusted for multiple comparisons. bMetabolite also found to differentiate three response groups.
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(attending neonatologist made the decision about length of
therapy). The dexamethasone was dosed as 0.15 mg/kg/day
for 3 days, then 0.10 mg/kg/day for 2–3 days, then 0.05 mg/
kg/day for 1–2 days, then 0.02 mg/kg/day for 1–2 days. The
RSS was significantly less after steroid treatment than before for both serum and urine samples. For paired serum
samples, median pre-RSS was 7.8, and median post-RSS
was 2.63 (P value = 0.0039). For paired urine samples, the
median pre-RSS was 5.16, and the median post-RSS was
2.57 (P value = 0.0039), Figure 1.
A total of 686 metabolites were assayed in both serum
and urine samples, and 197 of these were known entities.
Therefore, these 197 metabolites were included in the analysis. In serum, 11 metabolites were significantly different
between presteroid and poststeroid treatments (Table 2).
Serum gluconic acid displayed the largest median foldchange (139.8 times decreased with steroid therapy; P value
= 0.008). Serum caprylic acid had the largest increase in median fold change (5.3 times; P value = 0.008). In urine, 15 metabolites were significantly different between pre-steroid and
post-steroid therapy (Table 2). The largest decrease in the
median fold change was with isohexanoic acid (fold change
15.5; P value = 0.008), and the largest increase was with
sucrose (fold change = 2.09; P value = 0.0195). Regression
analysis results for baseline metabolite and change in RSS
are presented in Table 3. In serum, baseline xylitol levels are
most associated with the degree of clinical steroid response,
and in urine baseline saccharic acid is most associated.
Of the statistically significant metabolites in Table 2
(change with steroid treatment), caprylic acid in serum and
uridine in urine were also found to be significantly associated with degree of change in RSS in regression analyses.
However, the changes in metabolite amount with dexamethasone treatment were not statistically significant after multiple testing adjustments.
The MSEA results for serum and urine are shown in Figure 2.
The horizontal bars summarize the most significant metabolite
sets identified to change with dexamethasone therapy, and
the color intensities on the bars are based on their P values.
For both serum and urine, urea cycle, ammonia recycling, and
malate-aspartate shuttle pathways were the three most significantly enriched pathways (P values < 0.05) when comparing
pre-steroid and post-steroid therapy. All of these pathways are
implicated in energy homeostasis.
As expected, clinical improvement was variable with drug
treatment (Figure 4, top row). Therefore, we performed
a univariate regression analysis to investigate whether
changes in individual metabolite levels were associated with
change in RSS. The top three most correlated metabolites
for serum and urine are displayed in Figure 3. Change in
6 serum metabolites and 28 urine metabolites were associated with change in RSS. Because of the small samples
size, the majority of the associations (regression or correlation coefficients) did not retain their significance after adjusting for multiple comparisons. Urine metabolite gluconic acid
lactone was the most significantly associated with a correlation coefficient of 0.915. Changes in the two metabolites
threonic acid and isocitric acid were significantly associated with change in RSS for both serum and urine samples.

The most highly associated metabolites were capric acid in
serum and gluconic acid lactone in urine.
In the final exploratory analysis, we compared changes in
the metabolites among the three steroid response groups:
good, moderate, and poor responders. In both serum and
urine, none of the metabolites were significantly different
among the three groups using a P value of <0.05. However,
eight sera (uridine, saccharic acid, p-hydroxylphenyllactic
acid, phosphoethanolamine, kynurenine, isohexonix acid,
gluconic acid, and erythrose) and eight urine metabolites
(citrulline, uridine, trehalose, tagatose, mannitol, maltose, alpha-aminoadipic acid, and alloxanoic acid) were different between the three groups using a cutoff of <0.07 (Supplemental
Table S1). The patient-specific change in RSS and select
metabolites are displayed in Figure 4, with clinical response
color-coded as green (good responders), yellow (moderate
responders), and red (poor responders). Further research
with bigger sample size is needed to investigate the association of these metabolites with degree of steroid response.
DISCUSSION
Systemic steroid response is heterogeneous in preterm infants at risk for severe BPD, and the respiratory response
data from this study confirm this. Although pharmacogenomics is beginning to shed light on this variability in
drug response,8 pharmacometabolomic research has the
potential to unmask underlying physiology that contributes to drug response variability.9,10 In this cohort study,
we show that steroid treatment leads to changes in certain
serum and urinary metabolites, and that certain metabolite changes are correlated with the degree of respiratory
improvement after systemic dexamethasone therapy.
Gluconic acid (lactone) is a metabolite that is significant in
three of the analyses we performed: it is greatly decreased
Table 3. Significant association between the baseline metabolite and
change in RSS
β

P value

Correlation

Xylitol

−0.00210

0.005

−0.83

N-Acetylornithine

−0.00036

0.013

−0.78

Cystine

−0.00090

0.021

−0.75

0.00242

0.035

0.70

Metabolites
Serum

Kynurenic acid
Urine
Saccharic acida

0.00000

0.001

−0.89

N-Acetyl- d-tryptophan

−0.00002

0.003

−0.86

3,6-Anhydro-d-hexosea

−0.00052

0.004

−0.85

Uridine

−0.00066

0.015

−0.77

Gluconic acid lactonea

0.00000

0.017

−0.76

Hexaric acid

−0.00108

0.028

−0.72

Isoribose

−0.00021

0.037

−0.70

Maltotriitol

−0.00042

0.038

−0.69

0.00011

0.039

0.69

−0.00003

0.043

−0.68

Citrulline
Beta-gentiobiose

RSS, Respiratory Severity Score.
a
Change in metabolite levels associated with change in RSS.
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Metabolite Set Enrichment Overview

Serum
Urea Cycle
Ammonia Recycling
Malate-Aspartate Shuttle
Arginine and Proline Metabolism
Glucose-Alanine Cycle
Aspartate Metabolism
Glutathione Metabolism
Glycine and Serine Metabolism
Alanine Metabolism
Glutamate Metabolism
Warburg Effect
Beta-Alanine Metabolism
Phenylalanine and Tyrosine Metabolism
Carnitine Synthesis
Citric Acid Cycle
Homocysteine Degradation
Lactose Degradation
Methionine Metabolism
Fatty Acid Biosynthesis
Spermidine and Spermine Biosynthesis
Galactose Metabolism
Taurine and Hypotaurine Metabolism
Methylhistidine Metabolism
Starch and Sucrose Metabolism
Valine, Leucine and Isoleucine Degradation
Amino Sugar Metabolism
Purine Metabolism
Gluconeogenesis
Glycerolipid Metabolism
Cysteine Metabolism
Beta Oxidation of Very Long Chain Fatty Acids
Tryptophan Metabolism
Biotin Metabolism
Mitochondrial Electron Transport Chain
Lysine Degradation
Propanoate Metabolism
Nucleotide Sugars Metabolism
Phenylacetate Metabolism
Histidine Metabolism
Pantothenate and CoA Biosynthesis
Transfer of Acetyl Groups into Mitochondria
D-Arginine and D-Ornithine Metabolism
Trehalose Degradation
Tyrosine Metabolism
Nicotinate and Nicotinamide Metabolism
Phosphatidylethanolamine Biosynthesis
Oxidation of Branched Chain Fatty Acids Phytanic
Acid Peroxisomal Oxidation
Ketone Body Metabolism
Thyroid hormone synthesis

Urea Cycle
Ammonia Recycling
Malate-Aspartate Shuttle
Aspartate Metabolism
Glucose-Alanine Cycle
Galactose Metabolism
Glutathione Metabolism
Beta-Alanine Metabolism
Carnitine Synthesis
Arginine and Proline Metabolism
Alanine Metabolism
Phosphatidylethanolamine Biosynthesis
Methionine Metabolism
Spermidine and Spermine Biosynthesis
Citric Acid Cycle
Glycine and Serine Metabolism
Tryptophan Metabolism
Phenylalanine and Tyrosine Metabolism
Glutamate Metabolism
Homocysteine Degradation
Lactose Degradation
Warburg Effect
Purine Metabolism
Methylhistidine Metabolism
Glycerolipid Metabolism
Taurine and Hypotaurine Metabolism
Catecholamine Biosynthesis
Phosphatidylcholine Biosynthesis
Lysine Degradation
Starch and Sucrose Metabolism
Sphingolipid Metabolism
Tyrosine Metabolism
Amino Sugar Metabolism
Biotin Metabolism
Propanoate Metabolism
Cysteine Metabolism
Oxidation of Branched Chain Fatty Acids
Phytanic Acid Peroxisomal Oxidation
Gluconeogenesis
Phenylacetate Metabolism
Mitochondrial Electron Transport Chain
Selenoamino Acid Metabolism
Nucleotide Sugars Metabolism
D-Arginine and D-Ornithine Metabolism
Glycerol Phosphate Shuttle
Trehalose Degradation
Betaine Metabolism
Pantothenate and CoA Biosynthesis
Transfer of Acetyl Groups into Mitochondria
Pyrimidine Metabolism

P-value
9e-04

4e-01

7e-01

0

1

2

3

Fold Enrichment

Urine

4

0.0

P-value
1e-02

4e-01

8e-01

0.5

1.0

1.5

2.0

Fold Enrichment

2.5

Figure 2. Metabolite set enrichment analysis.

with steroid therapy, the degree of decrease correlated with
the degree of steroid response, and it is nearly significantly
different among good, moderate, and poor responders.
Urine gluconic acid lactone, uridine, and mannitol were
found to correlate with degree of steroid response. In all
three, the more the metabolite decreased with treatment,
the better the clinical response (more negative change in
RSS). Gluconic acid (gluconate) is an oxidation product of
glucose. The metabolism of gluconic acid is poorly understood in humans, but a recent study of human glucokinase
shows that small changes in gluconate concentration lead
to large shifts in the hexose monophosphate shunt.11 The
hexose monophosphate shunt produces nicotinamide adenine dinucleotide phosphate, a cofactor for glutathione reductase catalysis important in neutralizing oxidative stress.
In addition, this shunt produces ribose-5-phosphate, a precursor molecule for nucleotide synthesis. The exact role of
gluconic acid in human disease, let alone preterm infant
disease, is not known, but multiple metabolomics studies
have identified this molecule as a potential marker of inflammation and disease. Uridine is a nucleoside and has been
shown in animal models to inhibit inflammation and fibrosis
Clinical and Translational Science

in a model of lung fibrosis.12 In an animal model of arthritis,
direct uridine injection of the joint space prevented development of joint inflammation and inhibited local cytokine production.13 In ex vivo cell adhesion models and a rat model
of chemical-induced lung inflammation, uridine and/or
4-thiouridine decreases leukocyte adhesion, tissue edema,
and tumor necrosis factor-alpha levels.14 A decrease of this
anti-inflammatory metabolite with steroid treatment in good
responders may indicate the steroids are inhibiting inflammation in the lungs. The metabolite mannitol is thought to
arise from the microbiome. Mannitol is produced by lactic
acid bacteria,15 pseudomonal species,16 and streptococcal
species.17 Mannitol is a biomarker of congestive heart disease,17 which is increasingly recognized as an inflammatory
condition. In total, urine biomarkers associated with degree
of steroid response in BPD seem implicated in the inflammatory cascade and oxidative stress, consistent with known
disease physiology.
Fanos et al.18 found that gluconates are one of five
metabolites that, in urine samples collected shortly after
birth, can distinguish between preterm infants who go
on to develop BPD versus those who do not. A study on
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Change in RSS
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Figure 3. Regression results of change in metabolite with change in Respiratory Severity Score (RSS). The three most strongly
correlated metabolites in (a) serum and (b) urine are displayed.

the metabolomics of necrotizing enterocolitis showed a
marked increase in gluconic acid from urine samples of
infants with necrotizing enterocolitis.19 Gluconic acid is
the only metabolite statistically significantly different in the
cord blood of neonates with histologic chorioamnionitis
vs. controls, furthering its implication in inflammation.20
Thus, a decrease in gluconic acid with steroid treatment
in preterm infants with lung disease is consistent with
decreased inflammation. The greater the gluconic acid
decrease, the better the clinical response to steroids, indicating that this metabolite may be a quantitative biomarker of drug response.
Trans-4-hydroxyproline is decreased in serum after
steroid treatment. Trans-4-hydroxyproline is elevated
in patients with idiopathic pulmonary fibrosis.21 In 14
ventilator-dependent infants with BPD, high-dose dexamethasone treatment was associated with decreased
urinary trans-4-hydroxyproline at days 3, 6, 9, and 12 of
treatment, indicating suppressed collagen synthesis.22
In rats, sepsis-associated lung injury is associated with
increased pulmonary fibrosis and hydroxyproline content.
In these animals, hydroxyproline was more elevated in

animals ventilated with a high tidal volume as opposed to
a lower tidal volume, reflective of a more injurious ventilation strategy inducing more lung injury.23 In sum, it seems
that trans-4-hydroxyproline is a marker of lung injury and
fibrosis, so a decrease with steroid treatment is biologically
plausible.
Citric acid (citrate) and isocitric acid (isocitrate) were both
associated with the degree of RSS improvement after steroid
therapy. Both of these molecules are key intermediaries in
the tricarboxylic acid cycle, which is an important metabolic
pathway for the generation of ATP. If relatively higher levels
of citrate and isocitrate are associated with improved lung
function, this may imply that with steroid therapy the best
responders exhibit quieting of their tricarboxylic acid cycle
(and, thus, higher substrate availability), corresponding to
less energy demand. Metabolic reprogramming occurs in
human and animal models of chronic lung disease, implying
that metabolic and energy perturbations may be implicated
in BPD development and progression. In patients with BPD
and growth failure, resting metabolic expenditure is elevated
suggesting increased metabolic demand.24 Gene expression
profiles of newborn umbilical cord blood show that infants
www.cts-journal.com
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Figure 4. Metabolite change by clinical response group. Left panel displays serum results and right panel displays urine results. For
the absolute change in Respiratory Severity Score (RSS) in the top row, each bar represents an individual infant change in RSS with
steroid treatment. For the change in metabolite, each bar represents the group mean.

who go on to develop BPD have lower levels of genes involved in oxidative phosphorylation and other bioenergetic
pathways.25
Our study has strengths and weaknesses. A strength of
our study is the ability to recruit a homogeneous group of
preterm infants with severe lung disease and closely phenotype them before and after steroid treatment. Another
strength is protocolized and standard dexamethasone dosing in our NICU, so dose variability does not confound our
findings. Because extremely preterm infants treated with
dexamethasone are rare at our level IV NICU, and because
we limited our analysis to the first course of systemic dexamethasone, our sample size is small, and the statistical
power is limited. We have not prospectively validated these
findings. In addition, because the study was performed
Clinical and Translational Science

during routine clinical care, the timing of the “post” steroid
treatment sample was variable (collected when infants were
getting blood drawn for clinical reasons). This variability in
postdrug sample collection might confound the analysis,
but we do not have sufficient sample size to control for
this in the current cohort. Last, in this untargeted metabolomic study, we limited statistical analysis to only serum
and urine metabolites with known identities. This could prevent our discovery of novel metabolites. Because there is
so little known about pharmacometabolomics in neonates,
our group felt it important to share this hypothesis-generating type of data while we continue to increase the size of
our study cohort. In future research, we hope to secure the
funding required for unknown metabolite identification and
targeted quantification.
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Metabolomics have been used in the neonatal population to identify disease states, such as histologic chorioamnionitis,20 early and late-onset sepsis,26 cytomegalovirus,27
and intrauterine growth restriction.28 In addition, metabolomic studies have investigated whether BPD severity and
pulmonary hypertension can be predicted from umbilical
cord blood metabolomics.29 To our knowledge, this is the
first study investigating pharmacometabolomics in preterm
neonates. The power to understand how changes in biomarkers collected during routine clinical care correlate with
likelihood of wanted clinical response to a drug is a potentially powerful tool for precision therapeutics. This study
serves as an early investigation of pharmacometabolomics
in preterm infants, and the research group is actively expanding the patient cohort to create a fuller understanding
of the metabolomics of steroid response in preterm infants.
Supporting Information. Supplementary information accompanies this paper on the Clinical and Translational Science website
(www.cts-journal.com).
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